430 results about "Granulocyte" patented technology

Compounds of the present invention, alone and in combination with other active agents, find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to for example malignant melanomas, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

The present invention comprises a method to identify granulocytic cell genes that are differentially expressed upon exposure to a pathogen or in a sterile inflammatory disease by preparing a gene expression profile of a granulocytic cell population exposed to a pathogen or isolated from a subject having a sterile inflammatory disease and comparing that profile to a profile prepared from quiescent granulocytic cells. The present invention is particularly useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signaling molecules. The invention also includes methods to identify a therapeutic agent that modulates the expression of at least one gene in a granulocytic population. Genes which are differentially expressed during neutrophil contact with a pathogen, such as a virulent bacteria, or that are differentially expressed in a subject having a sterile inflammatory disease are of particular importance.

The present invention provides a highly sensitive method of diagnosing inflammatory bowel disease (IBD) in an individual. The method includes the steps of isolating a sample from the individual; determining by non-histological means whether the sample is positive for anti-neutrophil cytoplasmic antibodies (ANCA); determining whether the sample is positive for anti-Saccharomyces cerevisiae immunoglobulin A (ASCA-IgA); determining whether the sample is positive for anti-Saccharomyces cerevisiae immunoglobulin G (ASCA-IgG); and diagnosing the individual as having IBD when the sample is positive for ANCA, ASCA-IgA or ASCA-IgG, and diagnosing the individual as not having IBD when the sample is negative for ANCA, ASCA-IgA and ASCA-IgG, provided that the method does not include histological analysis of neutrophils.

The invention provides a chimeric antigen receptor (CAR) (a) an antigen binding domain of HN1 or SS, a transmembrane domain, and an intracellular T cell signaling domain, or (b) an antigen binding domain of SS1, a transmembrane domain, an intracellular T cell signaling domain, and a granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor 2 leader. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

A method useful for the enumeration of cell populations in a biological sample includes the steps of reacting in a single reaction mixture a sample, a first antibody labeled with a fluorochrome having a first emission spectrum and an additional antibody. The first antibody binds to an antigenic determinant differentially expressed on leukocytes and non-leukocytes. The additional antibody binds to an antigenic determinant differentially expressed on mature and immature granulocytes or myeloid cells, and is labeled either with the first fluorochrome or an additional fluorochrome having an emission spectrum distinguishable from the first emission spectrum. The reaction mixture can be mixed with a nucleic acid dye having an emission spectrum that overlaps with one of the first or additional emission spectra. The reaction mixture may be treated with a lytic system that differentially lyses non-nucleated red blood cells and conserves leukocytes. Populations of hematological cells are detected and enumerated using at least two parameters (fluorescence, optical, and electrical) for each population.

The invention provides methods of treating a disease selected from systemic sclerosis, rheumatoid arthritis, mastocytosis, and chronic eosinophilic leukemia comprising administering biaryl meta-pyrimidine compounds having the general structure (A) to a subject in need thereof. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the JAK kinase family, and various other specific receptor and non-receptor kinases.

The invention relates to a recombinant human granulocyte colony stimulating factor and one-step purifying process for chemical modifications, which employs the method of cation exchange chromatography, wherein one-step chromatography is utilized for obtaining high activity, high purity and high recovery ratio rhG-CSF and polyethylene glycol chemically modified rhG-CSF. The process is especially suitable for industrial production.

The invention relates to a polyethylene glycol modified protein separating and purifying method. The invention discloses a novel cation chromatography media MacroCap Sp which can induct protein surface charge distribution relation sensitively. The more positive charge on a protein surface, the stronger combination capability of the protein with the MacroCap Sp, and the higher ion gradient is needed for elution. By utilizing the above property, polyethylene glycol modified protein molecule can be effectively separated. The method comprises the following steps: (1) after modification of object protein by polyethylene glycol with active reaction group, adjusting pH value of a reaction solution, wherein the pH value should be lower than isoelectric point of the polyethylene glycol modified protein; (2) loading the reaction solution to balanced MacroCap Sp cation exchange columns; (3) adding a sodium salt solution to carry out ion gradient elution based on a balanced buffer solution, and collecting object peak. The method of the present invention is suitable for effective separation of recombinant human granulocyte stimulating factor modified by the polyethylene glycol and exenatide.

The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.

The invention discloses production method for a recombinant human granulocyte colony-stimulating factor. According to the invention, an engineered strain of an escherichia coli expressed recombinant human granulocyte colony-stimulating factor is cultured to obtain an inclusion body, the engineered strain of the escherichia coli expressed recombinant human granulocyte colony-stimulating factor is pKG931/HB101, a culture method comprises multiplication culture and culture in a fermentation cylinder, an antibiotic-free medium containing yeast and peptone is employed in both culture, a high pressure homogenizer is used for breaking of bacteria, and denaturation, renaturation and chromatography are carried out so as to obtain a high purity G-CSF stock solution. The production method provided by the invention has the advantages of a short production period, high production efficiency, a great production scale, especial suitability for industrial production and reduction in production cost.

The invention discloses a tumor targeting metal complex, a synthetic method and application. The synthetic method comprises the steps of connecting a ligand with a substituent group and a targeting molecule, complexing the ligand and metal ions, and synthesizing to obtain the tumor targeting metal complex, wherein the ligand is one of a phenanthroline derivative, a dipyridyl derivative, a benzimidazole derivative, a phenyl-pyridine derivative and a thiophene-pyridine derivative; the targeting molecule is one of biotin, folic acid, integrin, transferrin, cell-penetrating peptide, octa-poly-L-arginine, MUC-1 attached membrane protein, galactosamine, neovascular targeting peptide and a granulocyte-macrophage colony-stimulating factor; the metal ions are ruthenium, osmium, rhodium or iridium ions. The complex obtained by the method provided by the invention can be selectively absorbed by tumor cells, and induces apoptosis of the tumor cells. In a nude mouse tumor-bearing model, the tumor targeting metal complex can image and treat tumors, and the toxicity of organs and tissues is reduced.

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention discloses a new Chinese medicine composite for treating appendicitis and a preparation method thereof. The Chinese medicine composite is prepared by the following ingredients of grassleaf sweetflag rhizome, squama manitis, styrax, lysimachia foenum-graecum, lignum dalbergiae odoriferae, radix et rhizoma rhei, ligusticum chuanxiong, Lignum aquilariae resinatum, rhizoma cyperi, honeysuckle flower, Chinese violet, weeping forsythia, dandelion, stir-fried frankincense, stir-fried myrrh, radix sophorae flavescentis, ramulus cinnamomi, radix paeoniae alba, radix paeoniae rubra, folium isatidis, common andrographis herb, rhizoma sparganii and rhizoma curcumae, and the like. The Chinese medicine composite can be prepared to be any common oral preparation according to the conventional Chinese medicine preparation method. The Chinese medicine composite can obviously improve right lower quadrant pain, increased body temperature, emesia, neutrophilic leukocytosis and the like, effectively block appendix gangrene and perforation, and complicate localized or diffuse peritonitis, which has definite clinical effect, obvious curative effect and fast desired effect. Due to the combination of the medicines both as food and medicine according to state-promulgated pharmacopoeia, the Chinese medicine composite of the invention has the advantages of low cost, basically no toxic side effect and the like.

The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavernous plasma exudation, ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils; symptoms resulting from inflammation caused by bacterial infection, particularly accumulation of body fluid such as bronchocavernous plasma exudation ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils, can be alleviated effectively by ingesting or administering orally or parenterally a composition containing human-type lactoferrin as an effective component.

The invention relates to an immunonephelometry kit for detecting lipid carrier protein related to neutrophils gelatinase and a preparation method thereof; an application liquid bottle, an antibody suspending liquid bottle and a standard substance bottle are placed in a box body; application liquid is arranged in the application liquid bottle, and comprises the following components of: 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative, 1 percent to 20 percent of sodium chloride and 20mmol/l to 200mmol/l of buffer solution; the antibody suspending liquid bottle contains emulsion suspension which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, and the emulsion suspension has the following components of: 0.05 percent to 0.5 percent of emulsion which is coated with the monoclonal antibody of the lipid carrier protein related to the neutrophils gelatinase, 0.01 percent to 1 percent of surfactant, 0.01 percent to 0.5 percent of preservative and 20mmol/l to 200mmol/l of buffer solution; and the standard substance bottle contains the standard substances of the lipid carrier protein related to the neutrophils gelatinase. According to the invention, the mass quantitative detection on a biochemical instrument is realized.

The present invention relates to novel semi-synthetic macrolides with anti-inflammatory activity. More specifically, the present invention relates to 14- and 15-membered macrolides substituted at the 4" position, their pharmaceutically acceptable derivatives, their preparation methods and intermediates, pharmaceutical compositions containing them and Their activity and use in the treatment of human and animal inflammatory diseases and disorders, particularly diseases associated with excessive secretion of TNF-alpha, IL-1, IL-8, IL-2 or IL-5; and/or as Activity and use of inhibitors of lymphocyte hyperproliferation and/or granulocyte hyperdegranulation.